30 Spring Mill Drive
About VenatoRx PharmaceuticalsVenatoRx Pharmaceuticals is a private pharmaceutical company dedicated to the discovery and development of novel anti-infective agents to address the threat of antibiotic resistance.
CEO: Christopher J. Burns
CDO: Luigi Xerri
COO: Ezra Felker
CFO: James G. Murphy
CMO: Tim Henkel
10 articles with VenatoRx Pharmaceuticals
VenatoRx Pharmaceuticals is a world leader in antibacterial and antiviral drug research and development. VenatoRx’s lead product, VNRX-5133, is an injectable beta-lactamase inhibitor (BLI) that features uniquely potent and selective activity against both serine- and metallo-beta-lactamases.
VenatoRx Pharmaceuticals to Present in vitro, in vivo and Phase I Data for cefepime/VNRX-5133 at IDWeek 2018
VenatoRx Pharmaceuticals will feature its lead clinical antibacterial candidate, cefepime/VNRX-5133, at IDWeek 2018 which is taking place in San Francisco, CA this week from October 3-7, 2018.
VenatoRx Pharmaceuticals announced that it was named one of the “2018 Best Places to Work” in the Greater Philadelphia area by the Philadelphia Business Journal.
VenatoRx Pharmaceuticals to present at ASM Microbe in the New Agents Discovery Summary Session and Emerging Tech Talks
The company will also present five posters featuring its lead clinical antibacterial candidate, cefepime/VNRX-5133
VenatoRx Pharmaceuticals announced that its President and CEO, Christopher J. Burns, Ph.D., will present at the UBS Global Healthcare Conference on Monday, May 21, 2018 at 8:00am ET in Ballroom V at the Grand Hyatt New York. The presentation will be webcast at www.venatorx.com/UBS2018.
Pipeline Corner Presentation, Mini Oral Sessions and Paper Poster Session to take place April 22-23
VenatoRx Pharmaceuticals to Present its Lead Clinical Antibacterial Candidate, VNRX-5133, at the American Chemical Society National Meeting
President and CEO, Christopher J. Burns, Ph.D., will present at the First-Time Disclosure of Clinical Candidates Oral Symposium on March 21, 2018 at 3:15pm CT
VenatoRx Pharmaceuticals Receives Award for up to $16 Million from DTRA to Develop a Novel, First-in-Class Antibiotic as Countermeasure against Potential Drug-Resistant Biodefense Category A/B Respiratory Pathogens
VenatoRx announced that it has been awarded up to $16 million from the Defense Threat Reduction Agency (DTRA), an agency of the U.S. Department of Defense.
VenatoRx Pharmaceuticals Receives FDA’s QIDP and Fast Track Designations for Development of Its Lead Antibiotic Program
The designations were granted for both complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI).